Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Ofatumumab
Drug: Carboplatin
Drug: Etoposide
Procedure: CT Scan
Procedure: PET Scan
Genetic: Stem Cell Transplant (STC)

First Posted Date: 2011-10-24

Last Posted Date: 2023-12-19

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 38

Registration Number: NCT01458366

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Phase 2

Completed

Conditions: Urothelial Carcinoma

Interventions: Drug: Cabazitaxel
Drug: Neulasta
Procedure: CT Scan
Biological: Blood Draw

First Posted Date: 2011-09-21

Last Posted Date: 2017-11-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT01437488

Locations: 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cabazitaxel
Radiation: Intensity Modulated Radiation Therapy (IMRT)
Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist

First Posted Date: 2011-08-19

Last Posted Date: 2024-03-27

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 20

Registration Number: NCT01420250

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Acute Lymphoblastic Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
Chronic Eosinophilic Leukemia
Chronic Myelomonocytic Leukemia
Chronic Neutrophilic Leukemia
Essential Thrombocythemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Interventions: Drug: Fludarabine
Drug: Busulfan
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide (CY)
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Device: Allogeneic hematopoietic stem cell transplantation
Procedure: Peripheral blood stem cell transplantation (PBSCT)

First Posted Date: 2011-06-29

Last Posted Date: 2022-11-17

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 40

Registration Number: NCT01384513

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Not Applicable

Terminated

Conditions: Cancer

Interventions: Procedure: Insertion of Pressure Equalization (PE) Tubes
Other: Saline (Placebo)
Drug: Sodium Thiosulfate (STS)
Drug: Cisplatin

First Posted Date: 2011-06-09

Last Posted Date: 2017-10-18

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 1

Registration Number: NCT01369641

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer
Advanced Hepatocellular Carcinoma
HCC

Interventions: Drug: PD-0332991

First Posted Date: 2011-05-19

Last Posted Date: 2024-10-23

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 23

Registration Number: NCT01356628

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Pentostatin
Drug: Ofatumumab

First Posted Date: 2011-05-11

Last Posted Date: 2018-05-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT01352312

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Phase 1

Terminated

Conditions: Acute Leukemia
Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes
Non-Hodgkin's Lymphoma
Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy
Myeloma
Hematologic Malignancies
Hodgkin's Lymphoma

Interventions: Drug: Fludarabine
Drug: Thiotepa
Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Melphalan
Device: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 8

Registration Number: NCT01350258

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Plasma Cell Neoplasms
Chronic Myeloid Leukemia
Hodgkin's Disease
Aplastic Anemia
Myelodysplastic Syndromes
Lymphoma
Biphenotypic Leukemia
Acute Lymphocytic Leukemia

Interventions: Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil (MMF)
Drug: Tacrolimus
Device: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 28

Registration Number: NCT01350245

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Not Applicable

Terminated

Conditions: Sickle Cell Anemia
Sickle Cell-hemoglobin C Disease
Sickle Cell-β0-thalassemia

Interventions: Drug: Fludarabine
Drug: Cytarabine
Device: Cellular Infusions
Radiation: Total Body Irradiation
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Rituximab
Procedure: Plasmapheresis

First Posted Date: 2011-05-09

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 2

Registration Number: NCT01350232

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy